Document Detail


The role of the National Institute on Drug Abuse in the development of naltrexone.
MedLine Citation:
PMID:  6088469     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Naltrexone was administered to 114 opiate-addicted business executives and 15 opiate-addicted physicians within a highly structured abstinence-oriented aftercare program following an inpatient detoxification program that used clonidine. The majority of patients successfully completed 6 months of naltrexone treatment without missed visits or drug-positive urines, and were still opiate-free at 12- to 18-months follow-up. The most successful outcomes were achieved by those who had entered treatment with unequivocal job jeopardy. Our findings suggest that naltrexone can be an extremely useful adjunct in the treatment of opiate addiction when administered to employed, motivated patients within a highly structured therapeutic program.
Authors:
H M Ginzburg; W J Glass
Related Documents :
22953989 - Towards more effective robotic gait training for stroke rehabilitation: a review.
20441449 - Consumers' perspectives on successful and unsuccessful experiences in a drug treatment ...
10636609 - Drug treatment and 12-step program participation: the additive effects of integrated re...
539569 - Therapeutic community dropouts: criminal behavior five years after treatment.
11138709 - Therapeutic communities: diversity in treatment elements.
2593209 - Outcome of a unique youth drug abuse program: a follow-up study of clients of straight,...
19662689 - A profile of the resistance training practices of elite spanish club teams.
23007109 - Buprenorphine from detox and beyond: preliminary evaluation of a pilot program to incre...
10093249 - Appropriate training for northern physicians.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of clinical psychiatry     Volume:  45     ISSN:  0160-6689     ISO Abbreviation:  J Clin Psychiatry     Publication Date:  1984 Sep 
Date Detail:
Created Date:  1984-10-22     Completed Date:  1984-10-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7801243     Medline TA:  J Clin Psychiatry     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  4-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aftercare
Animals
Carcinogens
Clinical Trials as Topic
Clonidine / therapeutic use
Drug Administration Schedule
Drug Evaluation
Drug Evaluation, Preclinical
Drug and Narcotic Control
Female
Humans
Male
Mice
Motivation
Naloxone / analogs & derivatives*
Naltrexone / therapeutic use*,  toxicity
Opioid-Related Disorders / drug therapy,  rehabilitation*
Patient Compliance
Rats
United States
United States Substance Abuse and Mental Health Services Administration*
Chemical
Reg. No./Substance:
0/Carcinogens; 16590-41-3/Naltrexone; 4205-90-7/Clonidine; 465-65-6/Naloxone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Naltrexone in addicted business executives and physicians.
Next Document:  Redox properties of membrane-bound b-type cytochromes and a soluble c-type cytochrome of nitrate red...